Most pancreatic ductal adenocarcinoma (PDAC) develops from pancreatic epithelial cells bearing activating mutant KRAS genes through precancerous lesions, i.e. acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN). During pancreatic tumorigenesis, Hes1 expression starts with the transition from acinar cells to ADM, and continues during PanIN and PDAC formation, but the role of Hes1 in pancreatic tumorigenesis is not fully elucidated. Here we show that Hes1 plays an essential role in the initiation and progression of KRAS-driven pancreatic tumorigenesis. In vitro, activation of MAPK signaling due to EGF or mutant KRAS activation induced sustained Hes1 expression in pancreatic acinar cells. In vivo, acinar cell-specific activation of mutant KRAS by Elastase1-CreERT2;Kras G12D induced ADM/PanIN formation with Hes1 expression in mice, and genetic ablation of Hes1 in these mice dramatically suppressed PanIN formation. Gene expression analysis and lineage tracing revealed that Hes1 regulates acinar-to-ductal reprogramming-related genes and, in a Hes1-deficient state, mutant Kras-induced ADM could not progress into PanIN, but re-differentiated into acinar cells. In the Elastase1-CreERT2;Kras G12D ;Trp53 R172H mouse PDAC model, genetic ablation of Hes1 completely blocked PDAC formation by keeping PanIN lesions in low-grade conditions, in addition to reducing the occurrence of PanIN. Together, these findings indicate that mutant KRAS-induced Hes1 plays an essential role in PDAC initiation and progression by regulating acinar-to-ductal reprogramming-related genes.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United States [1] , and a highly lethal disease with a 5-year survival rate of only 5-10% [1, 2] . The extremely poor prognosis is due to the lack of early detection methods, preventive strategies, and effective treatments. Overcoming such a negative situation critically requires elucidation of the underlying molecular mechanisms of PDAC initiation and progression, as well as exploration of novel risk factors and treatment targets. PDAC is believed to arise from a spectrum of preneoplastic mucinous lesions with a ductal morphology, among which pancreatic intraepithelial neoplasia (PanIN) is most commonly observed in humans [3] . PanIN lesions are considered to progress stepwise to PDAC by accumulating multiple genetic alterations [2, 3] . Among these, activating mutations of the KRAS gene have been detected at the earliest stage and are thought to be essential for the initiation of PanIN. The significance of the KRAS mutation has been demonstrated in pancreatic cancer mouse models in which expression of mutant Kras in pancreatic cells recapitulates the development of PanIN and subsequent PDAC [4] . The cells of origin for PDAC have been explored using these mouse models, and acinar cells are currently recognized as the putative origin of PDAC, at least in mice [5] . Acinar cells bearing mutant Kras transform into PanIN through acinar-to-ductal metaplasia (ADM), which is characterized by the replacement of acinar cells with cells co-expressing ductal markers as well as acinar markers. This acinar-to-ductal reprogramming (ADR) is promoted by factors that induce ductal cell identity, such as Sox9 and Klf4, but suppressed by factors that preserve acinar cell properties, such as Ptf1a and Mist1 [5] [6] [7] [8] . Important signaling pathways for pancreatic development, including Notch signaling, are involved in ADR [9] , but it is still unknown how a KRAS mutation affects and controls signaling.
Hes1 is a transcriptional factor and thought to be a main target of the Notch signaling pathway [10] . In the embryonic stage, Hes1 is expressed in stem/progenitor cells and is thought to maintain these cells and play a role in their cell fate decision. Observations of pancreas hypoplasia following global Hes1 gene deletion in mice suggest that Hes1 has essential roles in pancreatic development [11] . In the adult pancreas, Hes1 is expressed in duct cells but not in acinar cells under normal conditions. In contrast, during tumorigenesis, Hes1 expression starts with the transition from acinar cells to ADM, and continues during PanIN and PDAC formation, suggesting an essential role in the initiation and progression of PDAC [4, 9] . Indeed, the importance of Hes1 in PDAC development was recently highlighted in a study reporting that embryonal Hes1 gene deletion accelerates ADM and subsequent PDAC formation in a Kras G12D -driven PDAC mouse model [12] . Because of the essential role of Hes1 in pancreatic development, we considered that Hes1 should be deleted in the adulthood rather than in the embryonic stage, especially for analyzing the PDAC mouse model.
In the present study, we first demonstrated that sustained Hes1 expression was induced in pancreatic cells by mutant KRAS activation. Furthermore, contrary to the previous report of embryonal Hes1 gene deletion, conditional knockout of Hes1 in adult pancreatic acinar cells dramatically suppressed the formation of Kras G12D -driven PanIN and PDAC lesions in mice. Here we provide evidence that Hes1 plays essential roles in multiple steps of PDAC initiation and progression by regulating ADR-related genes. Given our previous report showing the antitumor effect of a novel Hes1 inhibitor on pancreatic cancer cells in vitro and in vivo [13] , Hes1 could be a new preventive or therapeutic target for PDAC.
Results

Sustained Hes1 expression is induced by mutant KRAS activation in pancreatic carcinogenesis
To evaluate the role of Hes1 in pancreatic carcinogenesis, we first used immunohistochemistry to evaluate HES1 protein expression in normal pancreatic tissues and pancreatic lesions in surgically resected specimens. In normal pancreatic tissues, HES1 expression was detected in duct cells and centroacinar cells, but not in acinar cells, as previously reported [9] (Fig. 1a) . On the other hand, HES1 was broadly expressed in precancerous lesions (i.e., ADM and PanIN) to PDAC (Fig. 1a) . Additionally, analysis of The Cancer Genome Atlas (TCGA) database revealed that higher expression of Hes1 mRNA in PDAC specimens was significantly correlated with poor prognosis of PDAC patients (Fig. 1b) , suggesting an essential role of Hes1 in PDAC formation.
Recent studies revealed that at least in mice, Kras G12D -driven PanIN and PDAC develop from acinar cells via ADM [5] . Therefore, the absence of Hes1 expression in normal acinar cells but its presence in ADM/PanIN suggests that Hes1 is induced by the activation of mutant Kras and involved in ADM/PanIN formation. Indeed, expression of pERK1/2, which indicates mitogen-activated protein kinase (MAPK) signaling activation, was observed in ADM, PanIN, and PDAC, but not in acinar cells in human pancreatic specimens (Fig. 1a) .
To analyze the relationship between MAPK signaling activation and Hes1 expression, we performed in vitro experiments using 266-6 cells, a mouse acinar cell-derived cell line established by SV40 T antigen induction without Kras mutation. Upon treatment with epidermal growth factor (EGF) to activate MAPK signaling, phosphorylation of Erk1/2 peaked in 5 min and Hes1 mRNA was transiently increased for 90 min (Fig. 2a) . This induction of Erk1/2 phosphorylation and Hes1 expression was completely suppressed by the Mek inhibitor U0126 (Fig. 2b) , suggesting MAPK-specific Hes1 induction in pancreatic acinar cells. To activate of MAPK signaling by mutant Kras, tamoxifeninducible mutant KRAS (ER-KRAS G12V ) [14] was induced in 266-6 cells using a lentivirus expression system. Upon tamoxifen treatment, strong and persistent phosphorylation of Erk1/2 by mutant KRAS was confirmed in this model. Notably, this mutant KRAS activation induced a sustained Hes1 mRNA increase (Fig. 2c) . Again, U0126 treatment completely repressed Erk1/2 phosphorylation and the subsequent Hes1 mRNA increase, suggesting a direct association of mutant Kras activation and Hes1 induction (Fig. 2d) . To assess the involvement of Notch signaling in this Hes1 induction, we next analyzed the effect of inhibition of Notch signaling by gamma secretase inhibitor N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-(S)-phenylglycine t-butyl ester (DAPT) in 266-6 cells. As a result, DAPT partially repressed Hes1 mRNA expression in a dosedependent manner (Fig. S1A) . However, Hes1 upregulation by mutant Kras activation was not inhibited by treatment with DAPT, suggesting that Hes1 was induced by MAPK signaling in a Notch signaling-independent manner (Fig.  2e) . These findings indicate that sustained Hes1 expression was induced by mutant Kras activation via MAPK signaling in pancreatic acinar cells, and may have an important role in pancreatic tumorigenesis.
Hes1 is not essential for maintaining the homeostasis of adult pancreatic acinar cells
Hes1 has an essential role in pancreatic development [11] , but its role in adult acinar cells is not fully elucidated. To elucidate the role of Hes1 in adult pancreatic acinar cells by excluding the influence of Hes1 deletion at the developmental stage, we generated Elastase1-CreERT2;Hes1 flox/flox (E-Hes1-KO) mice in which the Hes1 gene can be deleted specifically in acinar cells in a tamoxifen-dependent manner (Fig. S2A ). E-Hes1-KO mice and Elastase1-CreERT2; Hes1 wt/wt (E-Hes1-WT) mice were administered tamoxifen subcutaneously at 4 weeks of age and evaluated up to 7 months of age (Fig. S2B) . Compared with E-Hes1-WT mice, the E-Hes1-KO mice showed no obvious morphologic differences in pancreas as evaluated by hematoxylin and eosin staining, as well as by immunohistochemistry for amylase, cytokeratin, insulin, and glucagon after 6 months (Fig. S2C ). Because Elastase1-Cre does not affect centroacinar cells and duct cells, Hes1 expression was observed in these cells in both types of mice (Fig. S2C) . Also, body weight, pancreatic weight, pancreas/body weight ratio, fasting blood glucose, and mRNA expression of several pancreatic differentiation marker genes were not significantly different between the two groups ( Fig. S2D-S2G ).
We then evaluated the role of Hes1 in pancreatic regeneration after acute pancreatitis. For this purpose, EHes1-WT and E-Hes1-KO mice were administered tamoxifen at 4 weeks of age and injected with cerulein for 2 consecutive days at 1 week after the tamoxifen administration. Pancreatic tissues were evaluated 2 and 7 days after cerulein administration (Fig. 3a, b) . In E-Hes1-WT mice at day 2, abundant ADMs expressing Hes1 developed, and some cleaved caspase-3-positive cells, indicating apoptosis, were observed (Fig. 3c) . At day 7, as previously reported [15] , E-Hes1-WT mice almost completely recovered from acute pancreatitis and showed normal pancreatic (Fig. 3d) . Notably, E-Hes1-KO mice also developed an equivalent level of abundant ADMs at day 2 as compared with E-Hes1-WT mice, but were negative for Hes1, confirming successful deletion of the Hes1 (Fig. 3c ).
Furthermore, E-Hes1-KO mice showed no differences in the induction of apoptosis at day 2 ( Fig. 3c , e), recovery from acute pancreatitis at day 7 ( Fig. 3d) , or in the pancreas/body weight ratio at day 7 ( Fig. 3f) . Taken together, our data 
Hes1 is required for Kras
G12D -driven PanIN formation
We then explored the role of Hes1 in the initiation of pancreatic tumorigenesis using a Kras
G12D
-driven mouse PanIN model. We generated Elastase1-CreERT2;Kras (Fig. 4a) . KE-Hes1-WT and KE-Hes1-KO mice were administered tamoxifen at 4 weeks of age and evaluated for up to 6 months after the administration (Fig. 4b) . In KE-Hes1-WT mice, some PanIN lesions positive for alcian blue staining and Hes1 immunostaining developed after 2 months (Fig. 4c ). In contrast, in KE-Hes1- Pancreatic tissues were evaluated by hematoxylin and eosin staining, immunofluorescent staining for amylase and CK19, and immunohistochemistry for Hes1 and cleaved caspase-3. e Number of cleaved caspase-3-positive cells of Elastase1-CreERT2;Hes1 wt/wt (EHes1-WT) mice and Elastase1-CreERT2;Hes1 flox/flox (E-Hes1-KO) mice at day 2. f Pancreas weight to body weight ratio in E-Hes1-WT and E-Hes1-KO mice at day 7. Scale bars: 50 µm KO mice, only a few PanIN lesions without Hes1 immunostaining due to gene deletion were observed (Fig. 4c) . The number of PanIN lesions in KE-Hes1-KO mice was significantly lower than that in KE-Hes1-WT mice (Fig. 4d) . This difference was more evident after 6 months. In KE-Hes1-WT mice, a number of PanIN lesions developed across the pancreas, whereas only focal lesions were found in KE-Hes1-KO mice (Fig. 4e) . The area of PanIN lesions positive for alcian blue was significantly smaller in KE-Hes1-KO mice compared with KE-Hes1-WT mice (Fig. 4f) . Thus, Hes1 deletion dramatically suppressed Kras G12D -driven PanIN formation in mice, suggesting an essential role of Hes1 in the development of PanIN, i.e., the initiation of pancreatic carcinogenesis.
Because our KE-Hes1-WT mice developed multiple lung tumors, as previously reported [16] , we could not observe these mice for more than 6 months, which prevented us from evaluating PDAC formation (Fig. S3A-S3B ).
Hes1 is not required for Kras G12D -driven ADM formation, but is necessary for further progression to PanIN
Pancreatitis can significantly accelerate the formation of ADM and subsequent PanIN in a Kras G12D -driven mouse model [17] . To evaluate the precise role of Hes1 in the stepwise development of ADM and PanIN, we applied cerulein-induced acute pancreatitis to our Kras G12D -driven mouse model. KE-Hes1-WT and KE-Hes1-KO mice were administered tamoxifen at 4 weeks of age and injected with cerulein for 2 consecutive days at 1 week after the tamoxifen administration. Pancreatic tissues were evaluated at day 2, 4, 7, and 21 ( Fig. 5a, b) . In KE-Hes1-WT mice, widespread ADM lesions with Hes1 immunostaining developed by 2 days, and were still observed on day 4. A few PanIN lesions positive for alcian blue were observed on day 7, and, at 21 days, pancreatic acinar cells were replaced by widespread PanIN lesions (Fig. 5c) . Thus, as previously reported, cerulein-induced pancreatitis strongly accelerated the formation of PanIN via ADM in KE-Hes1-WT mice. In stark contrast to these observations, in KE-Hes1-KO mice, widespread ADM lesions developed to the same extent as in KE-Hes1-WT mice in 2 days, but these Hes1-negative ADM lesions gradually regressed by day 4. Notably, KE-Hes1-KO mice almost completely recovered from acute pancreatitis within 7 days (Fig. 5c) , as is observed in E-Hes1-WT or EHes1-KO mice (Fig. 3d) . In addition, the PanIN lesions rarely formed by 21 days (Fig. 5c) , and the area of the lesions in KE-Hes1-KO mice was significantly smaller than that in KE-Hes1-WT mice (Fig. 5e) . Taken together, Hes1 deletion did not affect ADM formation, but almost completely suppressed Kras G12D -and pancreatitis-induced ADM prolongation and the subsequent formation of PanIN. These results suggest an essential role of Hes1 in the progression from ADM to PanIN.
Hes1-deficient
To elucidate this, we generated mice in which the lineage of cells can be traced by crossing Rosa26-LSLtdTomato mice with E-Hes1-WT, E-Hes1-KO, KE-Hes1-WT, or KE-Hes1-KO mice (Fig. 6a) . Once cerulein-induced acute pancreatitis developed, these labeled acinar cells transitioned to ADM lesions. If the ADM lesions are eliminated by cell death, the pancreatic tissue will be compensated for by non-labeled cells (i.e. nonrecombinated acinar cells or duct cells), and the ratio of labeled cells will decrease after recovery from pancreatitis. On the other hand, if the ADM lesions re-differentiate into acinar cells, the pancreatic tissue will be repaired by the labeled (i.e., recombinated) cells, and the ratio of labeled cells will not change, as previously reported [18] . Under these conditions, tamoxifen was administered to 4-week-old mice, and gene recombination efficiency in pancreatic acinar cells was evaluated by analyzing the ratio of tdTomatolabeled cells to amylase-positive acinar cells 1 week later (day 0). Another cohort of mice was injected with cerulein over 2 consecutive days, and the ratio of tdTomato-labeled cells to amylase-positive acinar cells was evaluated 2 and 14 days later (day 2 and 14) (Fig. 6b) . In E-Hes1-WT mice, 75.8% of acinar cells were labeled with tdTomato on day 0, and most of these cells transitioned to ADM lesions on day 2 and re-differentiated into acinar cells expressing amylase on day 14 (Fig. 6c) , resulting in an unaltered tdTomatopositive cell ratio (74.3%) as previously described [18] . On the other hand, in KE-Hes1-WT mice, most tdTomatolabeled acinar cells progressed into PanIN that was positive for tdTomato and CK19 but negative for amylase on day 14 (Fig. 6e) . Interestingly, not only in E-Hes1-KO mice but also in KE-Hes1-KO mice, the ratio of tdTomato-labeled cells was not different between day 0 and 14 (77.5 and 74.5% in E-Hes1-KO mice, respectively; Fig. S4 ; 79.6 and 74.3% in KE-Hes1-KO mice, respectively; Fig. 6d ) as is observed in E-Hes1-WT mice. In addition to these results, no significant differences in the number of cleaved caspase-3 positive cells were observed between KE-Hes1-WT mice and KE-Hes1-KO mice at acute pancreatitis day 2 (Fig. 5c,  d ). These results indicate that even with Kras G12D induction, Hes1-deficient ADM lesions did not progress to PanIN lesions, but instead re-differentiated into acinar cells, suggesting an essential role of Hes1 in Kras G12D -driven ADM prolongation and progression to PanIN.
Hes1 regulates ADR-related genes
Previous reports demonstrated that the Kras G12D -driven ADR is promoted by transcriptional factors that induce ductal cell identity, such as Sox9 and Klf4 [5, 6] , but suppressed by transcriptional factors that preserve acinar cell properties, such as Ptf1a and Mist1 [7, 8] . On the basis of the pivotal role of Notch/Hes1 signaling in the cell fate decision of pancreatic cells by regulating genes, including Sox9 and Ptf1a [10, 19] , we assessed the expression of these genes in our Kras G12D -driven mouse model with cerulein-induced acute pancreatitis (Fig. 6a,  b) . The expression of Sox9 mRNA in pancreatic tissues was significantly lower in KE-Hes1-KO mice compared with KE-Hes1-WT mice on day 2 ( Fig. 6g) when ADM formation was the most strongly induced. The weaker expression of Sox9 protein in ADM lesions in KE-Hes1-KO mice compared with KE-Hes1-WT mice was also confirmed by immunohistochemistry (Fig. 6f) . In contrast, expression of Ptf1a mRNA was higher in KE-Hes1-KO mice than in KE-Hes1-WT mice on day 2, although the difference was not significant (Fig. 6h) . These alterations in Sox9 and Ptf1a mRNA expression were not observed between E-Hes1-WT and E-Hes1-KO mice with ceruleininduced acute pancreatitis, suggesting that Kras-induced Hes1 plays an important role in regulating ADR-related genes in PanIN formation ( Fig. S5A and S5B ). To further investigate the relationship between Hes1 and Sox9, we performed in vitro experiments using 266-6 cells. Although we failed to create Hes1 homozygous knockout cells, probably because Hes1 is essential for surviving, we successfully established Hes1 heterozygous knockout cells using the CRISPR/Cas9 technique and also Hes1-overexpressing cells using lentivirus expression systems. After confirming the stepwise expression of Hes1 mRNA (Fig. S6A-S6C) , we assessed Sox9 mRNA in these cells. Sox9 expression was increased or decreased in a Hes1 expression-dependent manner (Fig. S6B, S6D ). The close relationship between Hes1 and Sox9 in the PDAC specimens was also demonstrated by analysis of the TCGA database. The mRNA expression of Hes1 and Sox9 (Fig.  S6E ) was positively correlated, and Sox9 was one of the genes most strongly correlated with Hes1 and vice versa (Fig. S6F-S6G ). These results suggest that Hes1 induced by Kras G12D could regulate the progression from ADM to PanIN by orchestrating ADR-related genes. (KPEHes1-KO) mice. Unfortunately, KPE mice died from subcutaneous sarcoma at~3 months after tamoxifen injection prior to PDAC formation ( Fig. S7A-S7B ), and therefore cerulein was administered to accelerate PDAC formation [20] . KPE-Hes1-WT and KPE-Hes1-KO mice were administered tamoxifen at 4 weeks of age and injected with cerulein for 2 consecutive days beginning 1 week after flox/flox (KEHes1-KO) mice at day 2. g, h Sox9 and Ptf1a mRNA expression in pancreatic tissues of KE-Hes1-WT mice and KE-Hes1-KO mice at day 2. **P < 0.01. Scale bars: 50 µm tamoxifen administration. Pancreatic tissues were evaluated after 2 months (Fig. 7a, b) . The KPE-Hes1-WT mouse pancreas was quite enlarged by massively formed PanIN lesions with prominent fibrosis and inflammatory cell infiltration (Fig. 7c) . PDAC developed in 46.7% (7/15) of the mice (Fig. 7e) . Hes1 expression in these PanIN and PDAC lesions was confirmed by immunohistochemistry (Fig. 7c) . In contrast, in KPE-Hes1-KO mice, the size of the pancreas was almost normal, and the pancreas/body weight ratio was significantly smaller than that in KPE-Hes1-WT mice (Fig. 7c, d ). PanIN lesions without Hes1 immunostaining developed (Fig. 7c) , but the number of alcian bluepositive PanIN lesions was significantly lower than that in KPE-Hes1-WT (Fig. 7f) . Notably, no PDAC formation was observed in KPE-Hes1-KO mice (0/10) (Fig. 7e) . Although to a much lower extent than in the KPE-Hes1-WT mice, a substantial number of PanIN lesions were formed in the KPE-Hes1-KO mice. In KPE-Hes1-WT mice, a broad spectrum of lesions ranging from PanIN1A, 1B, 2, 3 to invasive carcinoma was observed (Fig. S8A-S8B ). In contrast, in KPE-Hes1-KO mice, only low-grade PanIN lesions (i.e. PanIN1A, 1B, and 2; most frequently PanIN1A) developed, but high-grade PanIN lesions (i.e. PanIN2 and PanIN3) were rarely observed (Fig. S8A-S8B ). Thus, Hes1 was suggested to have an essential role in the development of PanIN but also in its progression and subsequent PDAC formation.
Hes1 is required for progression from PanIN to PDAC
Discussion
Hes1 is not expressed in normal pancreatic acinar cells, but once these cells enter the oncogenic process, Hes1 expression begins during the transition of acinar cells to ADM and continues during PanIN and PDAC formation. These observations as well as the importance of Hes1 in pancreatic development suggest a critical role for Hes1 in pancreatic carcinogenesis, but the detailed functions of Hes1 in adult ;Hes1-flox/flox (KPE-Hes1-KO) mice. Representative images showing the results of hematoxylin and eosin staining, alcian blue staining, and immunohistochemistry for Hes1. d-f Pancreas to body weight ratio, PDAC formation percentage, and area of lesions in KPE-Hes1-WT and KPE-Hes1-KO mice. *P < 0.05 and **P < 0.01. Scale bars: 50 µm pancreatic pathogenesis were not fully elucidated. Here we demonstrated that activation of MAPK signaling due to mutant KRAS activation induces sustained Hes1 expression in pancreatic acinar cells, and that this sustained Hes1 activation plays an essential role in the formation of PanIN from ADM by regulating ADR-related genes. We also demonstrated that Hes1 is necessary to progress into PDAC.
Hes1, which is transcriptionally activated by Notch signaling, is reported to have an essential role in early pancreatic development. Hes1-ablated mice exhibit severe pancreatic hypoplasia due to the depletion of pancreatic epithelial precursors [10, 11] . A recent report also showed that conditional Hes1 ablation in pancreatic progenitors disrupts the terminal differentiation of acinar cells [12] . Thus, Hes1 has an essential role in the maintenance and differentiation of pancreatic progenitor cells in the development of the pancreas. On the other hand, consistent with previous reports [4, 9, 21] , the present study clearly showed that Hes1 is not expressed in acinar cells in adult pancreas, but is confined to ductal cells. In contrast to detailed previous studies at the developmental stage, the role of Hes1 in adult acinar cells, the putative cell of origin of PDAC [5] , had not been analyzed. Therefore, to exclude the effect of Hes1 ablation on embryogenesis, we utilized Elastase1-CreERT2 mice for inducible and acinar cell-specific ablation of Hes1. As a result, reflecting the absence of Hes1 expression in acinar cells, acinar cell-specific Hes1 ablation in adult mice induced no obvious changes in the pancreatic morphology, size, or expression of differentiation markers compared with WT mice. Furthermore, even with induction of cerulein-induced acute pancreatitis, acinar cell-specific Hes1-ablated mice did not exhibit significant differences in susceptibility to pancreatic injury, ADM formation, or acinar cell regenerative ability compared to WT mice. Thus, we concluded that Hes1 is not essential for maintaining the homeostasis of adult mature acinar cells in either normal or injured conditions. These results were different from the recent report by Hidalgo-Sastre et al., in that Hes1 ablation impaired acinar cell terminal differentiation and regeneration from caerulein-induced acute pancreatitis. We believe that these differences are due to the difference of Creinducing mouse used for Hes1 ablation, i.e., Elastase1-CreERT2 mice in our work and Ptf1a-Cre in Hidalgo-Sastre's. As previously reported in Foxa2-Cre;Hes1 flox mice, conditional deletion of Hes1 in the endoderm results in a switch from ductal progenitor-to-acinar progenitor in the embryonic pancreas [22] . Although Ptf1a-Cre, which induces recombination in pancreatic multipotent progenitor cells in the embryonic stage, may be less efficient than Foxa2-Cre, it would be still be expected to induce similar fate switch in at least some pancreatic progenitor cells. We speculate that such a fate change might influence the properties of resulting adult acinar cells, either directly in transdifferentiated acinar cells or indirectly via secondary, non-cell autonomous effects.
In contrast to normal acinar cells, Hes1 expression is broadly observed in ADM, PanIN, and PDAC [4, 9, 21] . In particular, in the Kras-driven mouse model, induction of ectopic Hes1 expression was confirmed in the transition of acinar cells to ADM. From these findings, we hypothesized that activation of KRAS signaling induces Hes1 in acinar cells. Although several pathways are reported to activate Hes1 expression, such as Notch, Sonic hedgehog, Wnt, etc. [23, 24] , our observation of a similar distribution of pErk1/2 and Hes1 in ADM, PanIN, and PDAC supported our hypothesis. Furthermore, using an acinar cell line without Kras mutation, we showed that EGF treatment induced Erk1/2 phosphorylation and subsequent Hes1 mRNA expression, and also that induction of mutant KRAS in these cells induced persistent Erk1/2 phosphorylation and sustained Hes1 expression. Notably, these inductions of Hes1 were completely repressed by Mek inhibitor treatment, suggesting a MAPK signaling-dependent Hes1 induction in these cells. In the relationship between Ras/MAPK signaling and Hes1, both Notch signaling-dependent and -independent pathways are reported [9, 25, 26] . Our results from the in vitro experiment that a Notch inhibitor failed to suppress Hes1 induction by mutant KRAS activation suggests the existence of a Notch-independent pathway in pancreatic acinar cells. Together, these finding suggests that mutant KRAS activation could have a role in the induction of sustained Hes1 expression, especially in the initiation of pancreatic tumorigenesis.
To investigate the role of Hes1 in pancreatic cancer initiation, we utilized a Kras-driven mouse model. Recently, using Ptf1a-Cre;Kras G12D ;Hes1 flox/flox mice, Hidalgo-Sastre et al. reported that pancreas-specific Hes1 ablation increases ADM formation and accelerates PDAC formation in mice [12] . As described above, however, Hes1 has an essential role in pancreatic development. We had substantial concern about evaluating pancreatic cancer initiation from exocrine cells with altered properties due to Hes1 ablation by Ptf1a-Cre in the embryonic stages. Therefore, to exclude such influences by Hes1 ablation, we used Elastase1-CreERT2 mice that were confirmed to have normal homeostasis in adult pancreatic tissue. Surprisingly, contrary to the report by Hidalgo-Sastre et al., Hes1 ablation almost completely repressed the formation of PanIN lesions in both the Kras-driven and cerulein-accelerated Kras-driven mouse model. In WT mice, ADM lesions are formed by cerulein-induced pancreatitis and promptly re-differentiate into acinar cells, whereas ADM lesions persist and progress into PanIN lesions in Kras mutant mice [15] . We observed that ADM lesions were induced by pancreatitis in Hes1-ablated mice at the same levels as WT mice. More importantly, these Hes1-ablated ADM lesions were able to redifferentiate into acinar cells, even with the induction of a Kras mutation, based on our precise analyses with daily monitoring or lineage tracing techniques. These findings suggested that Hes1 is required for sustaining and achieving Kras-driven ADR. ADR is promoted by Sox9 and Klf4 [5, 6] , which induce ductal cell differentiation, and is suppressed by Ptf1a and Mist1 [7, 8] , which induce acinar cell differentiation. From this point of view, it is reasonable that Hes1, whose expression is restricted to ductal cells, is required for ADR. Indeed, in Kras-driven Hes1-ablated mice, we demonstrated that Sox9 expression is significantly reduced, but Ptf1a expression is increased after the induction of cerulein-induced pancreatitis. Given the previous reports that Hes1 and Sox9 interact with each other [19, 27] , it is highly likely that Hes1 orchestrates these ADR-related genes and promotes Kras-driven PanIN formation. This concept is further supported by the results of Hes1-dependent Sox9 expression derived from our in vitro/ in vivo experiment and analysis of the TCGA data. In summary, Hes1 has an essential role in the formation of PanIN from ADM in the initiation of pancreatic cancer. To analyze the role of Hes1 in pancreatic cancer progression, we utilized a cerulein-accelerated PDAC mouse model in which mutant Trp53 as well as mutant Kras were induced by Elastase1-CreERT2 so-called KPC mice [28] . As a result, PDAC formation in KPC mice was completely suppressed by Hes1 ablation. This results suggested that Hes1 plays an essential roles not only initiation but also progression of pancreatic cancer.
In conclusion, we showed that Hes1 plays essential roles in multiple steps in PDAC initiation and progression by regulating ADR-related genes.
Materials and methods
Human samples
For immunohistochemistry of human samples, surgically resected specimens were obtained from PDAC patients who had been admitted to Kyoto University Hospital (Kyoto, Japan). For analysis of the relationship between mRNA expression and prognosis in PDAC patients, mRNA expression of all the genes and prognostic data were extracted from the TCGA Research Network (https://ca ncergenome.nih.gov/). Correlations between two genes were explored with cBioPortal (http://www.cbioportal.org/) [29, 30] .
Animals
All procedures were performed while mice were anesthetized by chloral hydrate (Wako, Japan), isoflurane (Pfizer, New York, NY, USA), or diethyl ether (Sigma-Aldrich, St. Louis, MO, USA), and all efforts were made to minimize the number of animals used and their suffering. The Hes1 flox mice [31] , Pdx1-Cre mice [32] , Elastase1-CreERT2 mice [18] , LSL-Kras G12D mice [33] , LSL-Trp53 R172H mice [34] , and Rosa26-CAG-LSL-tdTomato-WPRE mice [35] were described previously.
At least five mice in each experimental group were considered to be needed, and randomization and blinding were not used for the analysis of mice model. Acute pancreatitis was induced by 8 hourly intraperitoneal injections of 100 µg/kg cerulein (Sigma-Aldrich) dissolved in phosphate-buffered saline for 2 consecutive days. For cerulein-induced pancreatitis, the mice were allowed access to food and water ad libitum.
Tamoxifen (Sigma-Aldrich) was dissolved in corn oil at a concentration of 20 mg/ml (Wako). Tamoxifen (200 mg/ kg body weight) was subcutaneously administered to 4-week-old mice.
Fasting blood glucose levels from tail vein blood were measured with a glucose meter after overnight fasting.
Histology
Tissue sections were fixed in 10% neutral phosphatebuffered formalin, embedded in paraffin, sectioned at a thickness of 5 µm, and stained with hematoxylin-eosin (Wako).
Cell culture 266-6 cells (American Type Culture Collection, Manassas, VA, USA) were maintained at 37°C under a humidified atmosphere of 5% CO 2 in Dulbecco's modified Eagle medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Gibco) and 100 μg/ml each of penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA).
Statistics
Statistical analysis was performed using JMP (SAS Institute, Cary, NC, USA) or Excel (Microsoft Corp., Redmond, WA, USA) software. A two-tailed Student's t test was used to analyze differences between two groups for continuous data. The chi-squared test was used for categorical data. Pearson's r correlation was used to analyze the correlation between two groups. The log-rank test was used in survival studies. A P value of <0.05 was considered statistically significant. For P values, the following scale was applied: *P < 0.05 and **P < 0.01. Data are presented as means ± SEM.
